Is Tirzepatide Safe?

Writer： admin Time：2025-06-13 11:12 Browse：℃

Based on the SURPASS clinical development program, the United States Drug Administration has approved tirzepatide as a treatment of type 2 diabetes, considering it safe for use in adults with this condition .

In the phase 3 SURPASS-1 trial, researchers found tirzepatide to have a safety profile comparable to that of other GLP-1 receptor agonists. In the phase 3 SURPASS-4 trial, the study authors ruled out excess cardiovascular risk as a safety concern of tirzepatide in T2D patients .

Safety studies for other uses of tirzepatide are still ongoing, and research into tirzerpatide’s use as a weight loss treatment (the SURMOUNT program) already indicates a favorable safety profile.

Where sold as a reference material or research chemical, tirzepatide must be handled only by qualified researchers and authorized laboratory personnel, bearing in mind the limitations on safety data to date.

Researchers may consult the Mounjaro (tirzepatide) package insert for details on the safe and effective administration of tirzepatide. We summarize relevant points on the peptide’s safe administration:

    · Tirzepatide is administered by subcutaneous injection, into the fatty tissue beneath the skin (usually in the abdomen). It is best practice to rotate the injection site with each injection.

    · Tirzepatide should not be administered to subjects who have a history of medullary thyroid carcinoma, as it has been found to cause thyroid C-cell tumors in rats. Tirzepatide is also contraindicated in subjects with Multiple Endocrine Neoplasia         syndrome type 2 (MEN 2).

    · Subjects who are receiving insulin or an insulin secretagogue together with tirzepatide should be monitored for hypoglycemia. 

     · The peptide may delay absorption of certain oral medications. Subjects who are being administered drugs with a narrow therapeutic index should also be monitored.